Etoposide

Etoposide (エトポシド)

一行要約

Topoisomerase II 阻害薬 (podophyllotoxin 誘導体)。Platinum-chemotherapy (Cisplatin / Carboplatin) との併用 (EP 療法) が SCLC の 1L backbone として 30 年以上の標準地位を維持する。ES-SCLC では PD-L1-inhibitor (Atezolizumab + EP は IMpower133、Horn et al. NEnglJMed 2018; Durvalumab + EP は CASPIAN、Paz-Ares et al. Lancet 2019) + EP が現在の 1L 標準。LS-SCLC では Cisplatin + Etoposide + concurrent thoracic RT (Turrisi et al. NEnglJMed 1999 の加速過分割照射 + EP) が curative intent 治療。LCNEC adjuvant では JCOG1205-1206 (Eba et al. JpnJClinOncol 2014) が EP vs IP を比較し、現在も SCLC / LCNEC 治療の根幹を担い続けている。

主要エビデンス

LS-SCLC

Turrisi et al. NEnglJMed 1999 が EP + 1 日 2 回 (accelerated hyperfractionated) 照射 vs 1 日 1 回照射で 5-yr OS 26% vs 16% を示し、加速過分割照射 + EP が LS-SCLC の curative intent 標準として定着。日本でも Kubota et al. LancetOncol 2014 (JCOG0202) が CDDP + ETP + AHRT vs CDDP + CPT-11 + AHRT で EP backbone の優越性を確認。Recent radiation pneumonitis incidence は Doshita et al. AdvRadiatOncol 2023 が AHRT + chemo の RP 発生率を報告。

ES-SCLC (pre-IO era)

Noda et al. NEnglJMed 2002 (JCOG9511) は Irinotecan + Cisplatin が EP より OS 優越を示したが、西洋の確認試験 (Lara et al. JClinOncol 2009 = SWOG0124、Hanna et al. JClinOncol 2006) で再現されず → 地域差議論が継続。日本では IP の選択肢として残存し、Satouchi et al. JClinOncol 2014 (CDDP+AMR vs CDDP+CPT-11) も比較対象として並走。Bevacizumab 併用 Horn et al. JClinOncol 2009 (ECOG E3501) はその後 phase III で benefit 示せず。

ES-SCLC (IO + EP era)

Horn et al. NEnglJMed 2018 (IMpower133) が Atezolizumab + Carboplatin + Etoposide の OS HR 0.70 (12.3 vs 10.3 mo) を達成、Paz-Ares et al. Lancet 2019 (CASPIAN) が Durvalumab + Platinum + Etoposide で OS HR 0.73 を確認し、IO + EP が標準化。長期 follow-up は Liu et al. JClinOncol 2021 が 3-yr OS の倍増を示した。Pembrolizumab + EP は Rudin et al. JClinOncol 2020 (KEYNOTE-604) で OS の primary endpoint 達成せず。Ipilimumab + EP は Reck et al. JClinOncol 2016 でも benefit 示せず → CTLA-4 戦略は ES-SCLC で失敗。Poor PS subset への展開は Asao et al. BMCCancer 2022 / Asao et al. LancetRespirMed 2025 (NEJ045A) が durvalumab + EP の poor PS 集団での feasibility を示した。

ES-SCLC maintenance / 2L

新たな maintenance strategy として Paz-Ares et al. Lancet 2025 (IMforte) が lurbinectedin + atezolizumab で PFS / OS 改善を示し、EP induction 後の maintenance に第 2 軸を加えた。2L 領域では Mountzios et al. NEnglJMed 2025 が Tarlatamab (DLL3-CD3 BiTE) で platinum 後 OS benefit を示し EP 後の選択肢が拡大。

LCNEC

LCNEC adjuvant では Eba et al. JpnJClinOncol 2014 (JCOG1205-1206) が IP vs EP を比較。stage IV LCNEC では Niho et al. JThoracOncol 2013 が CDDP+CPT-11 を、Derks et al. ClinCancerRes 2018 が分子サブタイプによる EP / NSCLC-chemo 感受性差を示した。

メカニズム

Topoisomerase II inhibition:

• Etoposide は topoisomerase II-DNA cleavable complex を安定化 → DNA 二重鎖切断 (DSB) 蓄積 → apoptosis
• G2/M phase 感受性が高い → 増殖速度の速い SCLC に有効
• Podophyllotoxin 誘導体 (植物アルカロイド由来)

Platinum との相乗効果:

• Platinum は DNA crosslink → DNA repair 過程で topoisomerase II 依存性上昇 → Etoposide 感受性増強
• EP doublet は DNA damage の complementary mechanisms

Etoposide phosphate: Water-soluble prodrug → esterase で迅速に active form に変換。IV 投与時の安定性・利便性向上。

主要毒性: 骨髄抑制 (neutropenia が dose-limiting)、脱毛、消化器症状。Secondary leukemia (t-MDS/AML) の累積リスク (topoisomerase II 関連 11q23 rearrangement)。

臨床位置づけ

• ES-SCLC 1L: Atezolizumab + Carboplatin + Etoposide (IMpower133) or Durvalumab + Platinum + Etoposide (CASPIAN) が標準
• LS-SCLC: Cisplatin + Etoposide + concurrent thoracic RT → curative intent
• 胚細胞腫瘍: BEP 療法 (Bleomycin + Etoposide + Cisplatin) の backbone
• NSCLC: EP 療法の出番は限定的 (SCLC 特異的位置づけ)
• 経口 Etoposide: Metronomic 経口投与 (再発 SCLC) は活動あるが標準化されていない

Open Questions

• EP の代替 backbone: Lurbinectedin / DLL3-targeted-therapy (Tarlatamab) が EP-free 戦略を可能にするか
• LS-SCLC IO 併用: ADRIATIC (Durvalumab maintenance post-CRT) の成功 → EP+RT+IO の最適 sequencing
• Etoposide 耐性: Topoisomerase II downregulation、drug efflux (MDR1/P-gp)
• Secondary leukemia 累積リスク: Long-term survivor での t-MDS/AML surveillance
• IP vs EP 再検証: Molecular subtype 別の感受性差 (ASCL1 vs NEUROD1)

重要論文 Top 10

1. ★★★★★ Horn et al. NEnglJMed 2018 — IMpower133 — IO + EP ES-SCLC 1L 標準化
2. ★★★★★ Paz-Ares et al. Lancet 2019 — CASPIAN — Durvalumab + EP ES-SCLC 確認
3. ★★★★★ Turrisi et al. NEnglJMed 1999 — LS-SCLC EP + 加速過分割照射
4. ★★★★★ Noda et al. NEnglJMed 2002 — JCOG9511 — IP vs EP (日本)
5. ★★★★ Paz-Ares et al. Lancet 2025 — IMforte — EP induction 後 maintenance

関連エンティティ・概念

• 関連 class: Platinum-chemotherapy (EP doublet partner), PD-L1-inhibitor (IO+EP backbone), Irinotecan-Topotecan (SCLC 2L 競合 / IP 代替), DLL3-targeted-therapy (SCLC 新規 modality)
• 関連概念: SCLC-molecular-subtypes
• 試験: IMpower133 / CASPIAN / JCOG9511 / ADRIATIC
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 340 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Wang et al. CancerRes 2026 — VGF-Mediated mitochondrial remodeling fuels lung adenocarcinoma brain metastasis
• Chen et al. FrontOncol 2026 — Stereotactic radiotherapy for brain metastases indications, dose fractionation, technological innovations, and evolving
• Lu et al. JClinOncol 2026 — Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for

Basic-Immunotherapy

• Brennan et al. CellRepMed 2026 — Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration
• Gonzalez et al. JImmunotherCancer 2026 — Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer

Basic-Liquid-biopsy

• Ajay et al. JCOPrecisOncol 2025 — Comprehensive analysis of the value of dynamic changes in circulating tumor DNA in small cell lung cancer

Basic-Neutrophil and myeloid cell

• Baron et al. FrontOncol 2025 — Neutrophil extracellular traps are associated with poor response to neoadjuvant therapy and poor survival in pediatric

Basic-Oncogene and genetics

• Wong et al. Cell 2026 — A recipe for chaos extrachromosomal DNA and the hallmarks of cancer
• Yap et al. Cell 2026 — Targeting genomic instability in cancer
• Wang et al. SignalTransductTargetTher 2026 — Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous

Basic-Others

• Hinterleitner et al. Cell 2026 — Senescence in cancer hallmarks, paradoxes, and therapeutic promise
• Scholz et al. Nature 2026 — RNA-triggered cell killing with crispr-cas12a2

Clinical-NEC

• Sen et al. LancetOncol 2025 — Pulmonary neuroendocrine neoplasms the molecular landscape, therapeutic challenges, and diagnosis and management

Clinical-NSCLC-Driver negative

• Shimizu et al. CancerSci 2026 — Atezolizumab + chemotherapy in older patients with lung cancer in japan
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy

Clinical-NSCLC-EGFR

• Okamoto et al. LungCancer 2026 — Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and

Clinical-SCLC

• Sethakorn et al. Cancer 2026 — The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer
• Trotta et al. Cell 2026 — Excessive vascular integrity restricts anti-tumor immunity
• Wang et al. CellRepMed 2026 — Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and
• Zhang et al. FrontImmunol 2026 — First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain
• Liu et al. JAMAOncol 2026 — First-line serplulimab in extensive-stage small cell lung cancer secondary analysis of the ASTRUM-005 phase 3
• Miyauchi et al. JTOClinResRep 2025 — J-TAIL-2 A prospective, observational study of atezolizumab combined with carboplatin and etoposide in patients with
• Paz-Ares et al. Lancet 2025 — Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage
• Paulson et al. LancetOncol 2025 — Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after
• Asao et al. LancetRespirMed 2025 — Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer
• Reguart et al. LancetRespirMed 2025 — Rethinking immunotherapy in patients with SCLC with poor performance status
• Zhao et al. SignalTransductTargetTher 2026 — Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01) a

Clinical-Thymic

• Masui et al. ExpertRevAnticancerTher 2025 — An update on the therapeutic options for metastatic thymomas and thymic carcinomas
• Riely et al. JNatlComprCancNetw 2025 — Thymomas and thymic carcinomas, version 2.2025, NCCN clinical practice guidelines in oncology